Literature DB >> 28075490

Soluble transferrin receptor and risk of type 2 diabetes in the obese and nonobese.

José C Fernández-Cao1,2, Victoria Arija1,3,4, Núria Aranda1,4, Josep Basora3,4,5,6, Javier Diez-Espino6,7, Ramón Estruch6,8, Montse Fitó6,9, Dolores Corella6,10, Jordi Salas-Salvadó4,5,6.   

Abstract

BACKGROUND: Studies evaluating the relationship between soluble transferrin receptor (sTfR), a biomarker inversely related to body iron stores, and risk of type 2 diabetes mellitus (T2DM) are scarce and inconclusive. Furthermore, sTfR concentrations have been observed to be significantly higher in obese than in nonobese individuals. Therefore, the aim of this study was to assess the relationship between sTfR and the risk of T2DM in obese and nonobese subjects.
DESIGN: A nested case-control study of 153 cases of newly diagnosed diabetic subjects, 73 obese and 80 nonobese, and 306 individually matched controls, 138 obese and 166 nonobese, who did not develop T2DM for a median 6-year follow-up (interquartile range: 3·9-6·5) was conducted using data from the PREvention with MEDiterranean Diet (PREDIMED) cohort (http://www.controlled-trials.com/ISRCTN35739639). Cases and controls were matched for age (≤ 67 vs. > 67 years), gender, dietary intervention group and BMI (≤ 27 vs. > 27 kg/m2 ).
RESULTS: Waist circumference is the main determinant of sTfR concentrations in the whole sample (β = 0·476, P < 0·001), in the obese (β = 0·802, P < 0·001) and the nonobese (β = 0·455, P = 0·003). Furthermore, sTfR is directly associated with the risk of T2DM in obese individuals (OR = 2·79; 95% CI: 1·35-5·77, P = 0·005) and inversely associated in nonobese individuals (OR = 0·40; 95% CI: 0·20-0·79, P = 0·015).
CONCLUSIONS: The association between sTfR levels and risk of T2DM in a population at high cardiovascular risk depend on the presence or absence of obesity. While in nonobese subjects elevated sTfR levels are associated with a decreased risk of developing T2DM, in obese subjects the risk increases. This suggests that obesity alters the relationship between sTfR and T2DM incidence.
© 2017 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  zzm321990PREDIMEDzzm321990; Body iron stores; nested case-control; obesity; soluble transferrin receptor; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 28075490     DOI: 10.1111/eci.12725

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Hepcidin, soluble transferrin receptor and IL-6 levels in obese children and adolescents with and without type 2 diabetes mellitus/impaired glucose tolerance and their association with obstructive sleep apnea.

Authors:  S Shalitin; V Deutsch; R Tauman
Journal:  J Endocrinol Invest       Date:  2018-01-05       Impact factor: 4.256

2.  Response to "Relationship between soluble transferrin receptor and type 2 diabetes mellitus: A meta-analysis".

Authors:  Jingfang Liu
Journal:  J Diabetes Investig       Date:  2021-02-20       Impact factor: 4.232

3.  Ferritin, transferrin, and transferrin receptor in relation to metabolic obesity phenotypes: Findings from the China Health and Nutrition Survey.

Authors:  Ziyang Ren; Xingqi Cao; Chenxi Li; Jingyun Zhang; Xueqin Li; Peige Song; Yimin Zhu; Zuyun Liu
Journal:  Front Public Health       Date:  2022-08-26

4.  Iron metabolism and type 2 diabetes mellitus: A meta-analysis and systematic review.

Authors:  Jingfang Liu; Qingxiu Li; Yaxian Yang; Lihua Ma
Journal:  J Diabetes Investig       Date:  2020-02-23       Impact factor: 4.232

Review 5.  Iron Metabolism in Obesity and Metabolic Syndrome.

Authors:  Álvaro González-Domínguez; Francisco M Visiedo-García; Jesús Domínguez-Riscart; Raúl González-Domínguez; Rosa M Mateos; Alfonso María Lechuga-Sancho
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.